INVESTORS
Why invest?
The ability to degrade otherwise undruggable intracellular disease causing targets is one of the most exciting new innovations in medicine. Despite remarkable pre-clinical and clinical data showing degradation of soluble disease-causing proteins and peptides; to date, none - have been able to degrade larger disease causing targets such as dysfunctional organelles, aggregated proteins, biomolecular condensates or multiprotein inflammatory or oncogenic signaling complexes. Casma’s PHLYT™ platform harnesses the only known pathway in the cell that is capable of degrading these large complex disease targets in order to treat patients with multiple unmet medical needs.